Australia has started the world's first immunotherapy sessions for babies with peanut allergy, a food reaction that could be fatal in some cases. The oral immunotherapy will be started in five states, making it available for the first time in hospitals and ouside of the clinical trials. &nbsp;

Babies aged under 12 months who have peanut allergy can undergo the&nbsp;immunotherapy. Australia's National Allergy Centre of Excellence (NACE) hopes to extend it to more areas if it is effective.

Noting that there has been no widely available treatment for peanut allegey, director &nbsp;of NACE Prof Kirsten Perrett said the new therapy sessons aim "to change the way the most common food allergy in Asustralian children is managed."

Also read:&nbsp;<a href="https://www.wionews.com/science/zombie-viruses-hidden-in-ancient-genes-may-have-accelerated-cancer-study-745570">Zombie viruses hidden in ancient genes may have accelerated cancer: Study</a>

"Ultimately, we want to change the trajectory of allergic disease in Australia so that more children can go to school without the risk of a life-threatening peanut reaction," Australian Broadcasting Corporation quoted Perrett as saying.

<h2>What is peanut allergy immunotherapy?</h2>

The treatment involves giving carefully measured doses of peanut powder to the babies over a period of time.

Also read:&nbsp;<a href="https://www.wionews.com/science/study-shows-strong-links-between-losing-loved-ones-and-ageing-745671">Study shows 'strong links' between losing loved ones and biological ageing</a> 
 
Eventually, the children will reach a "maintenance dose" which can be continued for two years before stopping to see if the treatment has been effective, ABC quoted programme lead Dr Tim Brettig as saying.

<h2>What is peanut allergy?</h2>

One of the most common food allergies, peanut allergy happens when body identifies peanuts or peanut-containing food as harmful and generates an immune reaction.

The allergy symptoms include rashes, vomiting, hives, swelling, sneezing, asthma attack, abdominal pain, drop in blood pressure, diarrhea.

In worst cases, it could lead to cardiac arrests. 
 
(with inputs from agencies) 
&nbsp;

Australia has started the world's first immunotherapy sessions for babies with peanut allergy, a food reaction that could be fatal in some cases. The oral immunotherapy will be started in five states, making it available for the first time in hospitals and ouside of the clinical trials.

Australia has started the world's first immunotherapy sessions for babies with peanut allergy, a food reaction that could be fatal in some cases. The oral immunotherapy will be started in five states, making it available for the first time in hospitals and ouside of the clinical trials. Babies aged under 12 months who have peanut allergy can undergo the immunotherapy. Australia's National Allergy Centre of Excellence (NACE) hopes to extend it to more areas if it is effective. Noting that there has been no widely available treatment for peanut allegey, director of NACE Prof Kirsten Perrett said the new therapy sessons aim "to change the way the most common food allergy in Asustralian children is managed." Also read: Zombie viruses hidden in ancient genes may have accelerated cancer: Study "Ultimately, we want to change the trajectory of allergic disease in Australia so that more children can go to school without the risk of a life-threatening peanut reaction," Australian Broadcasting Corporation quoted Perrett as saying. What is peanut allergy immunotherapy? The treatment involves giving carefully measured doses of peanut powder to the babies over a period of time. Also read: Study shows 'strong links' between losing loved ones and biological ageing Eventually, the children will reach a "maintenance dose" which can be continued for two years before stopping to see if the treatment has been effective, ABC quoted programme lead Dr Tim Brettig as saying. What is peanut allergy? One of the most common food allergies, peanut allergy happens when body identifies peanuts or peanut-containing food as harmful and generates an immune reaction. The allergy symptoms include rashes, vomiting, hives, swelling, sneezing, asthma attack, abdominal pain, drop in blood pressure, diarrhea. In worst cases, it could lead to cardiac arrests. (with inputs from agencies)

World's first immunotherapy for peanut allergy in babies starts in Australia

A 28-year-old woman in the United States, who describes herself as being "allergic to gravity", has revealed that she spends 23 hours in bed and can't stand for more than three minutes without passing out. Molly Gambhir tells you all about this bizarre syndrome.

WION Fineprint | Woman claims she is allergic to gravity

Let us take a look at stories generating interest across WION's social media channels.

Trending on WION | Women 'allergic to gravity' spends 23 hours in bed due to  rare condition

Scientists have&nbsp;discovered a natural protein that stops allergies and autoimmune conditions, in a recent study.

The research published in the journal Cell on Thursday describes&nbsp;in detail&nbsp;a natural way the body prevents autoimmune disease and allergies. The process is driven by a protein in the body called neuritin.

Professor Carola Vinuesa from the Australian National University said, "We found this absolutely fascinating mechanism of our own bodies that stops the production of rogue antibodies that can cause either autoimmunity or allergies."

"It's been known for years that neuritin has a role in the brain and in the nervous system but we found an abundance of neuritin in the immune system and its mechanism - which has never been described in biology.

"We have shown it is one of our immune system's own mechanisms to prevent autoimmunity and allergy and now we have the evidence, we can go on to harness that for treatment."

The researchers say they set out over five years ago to bridge a knowledge gap on how the immune system works following an educated guess that neuritin might have a regulatory function in stopping allergies and autoimmune disease.

The study, published today in Cell, found neuritin can prevent the production of pathogenic antibodies.

"It is an incredible discovery. We saw that in the absence of neuritin there is increased susceptibility to death from anaphylaxis, highlighting its role in the prevention of life-threatening allergies," first author, ANU researcher Dr Paula Gonzalez Figueroa, said.

For people with allergies, when the immune system overreacts to allergens - like pollen, dust or peanut butter - it produces antibodies called Immunoglobulin E, (IgE).

Allergies happen when the body produces excessive IgE in response to otherwise harmless substances, leading to the release of histamine that causes allergic reactions.

"We have discovered neuritin prevents excessive formation of IgE that is typically associated with some common forms of allergy and food intolerances," Professor Vinuesa said.

Many autoimmune diseases are caused or exacerbated by antibodies that go on to destroy our own tissues and cause autoimmune diseases like lupus and rheumatoid arthritis.

"There are over 80 autoimmune diseases, in many of them we find antibodies that bind to our own tissues and attack us instead of targeting pathogens - viruses and bacteria," Dr Paula Gonzalez-Figueroa said.

"We found neuritin suppresses formation of rogue plasma cells which are the cells that produce harmful antibodies."

The researchers hope the discovery will now form the basis of new treatments.

"This could be more than a new drug - it could be a completely new approach to treat allergies and autoimmune diseases," Professor Vinuesa said.

"If this approach was successful, we would not need to deplete important immune cells nor dampen the entire immune system; instead, we would only need to use the proteins our own body uses to ensure immune tolerance.

"Allergies and autoimmune diseases are both on the rise and we hope this will give us a new way to tackle them."

Scientists have discovered a natural protein that stops allergies and autoimmune conditions, in a recent study. The research published in the journal Cell on Thursday describes in detail a natural way the body prevents autoimmune disease and allergies.

Scientists have discovered a natural protein that stops allergies and autoimmune conditions, in a recent study. The research published in the journal Cell on Thursday describes in detail a natural way the body prevents autoimmune disease and allergies. The process is driven by a protein in the body called neuritin. Professor Carola Vinuesa from the Australian National University said, "We found this absolutely fascinating mechanism of our own bodies that stops the production of rogue antibodies that can cause either autoimmunity or allergies." "It's been known for years that neuritin has a role in the brain and in the nervous system but we found an abundance of neuritin in the immune system and its mechanism - which has never been described in biology. "We have shown it is one of our immune system's own mechanisms to prevent autoimmunity and allergy and now we have the evidence, we can go on to harness that for treatment." The researchers say they set out over five years ago to bridge a knowledge gap on how the immune system works following an educated guess that neuritin might have a regulatory function in stopping allergies and autoimmune disease. The study, published today in Cell, found neuritin can prevent the production of pathogenic antibodies. "It is an incredible discovery. We saw that in the absence of neuritin there is increased susceptibility to death from anaphylaxis, highlighting its role in the prevention of life-threatening allergies," first author, ANU researcher Dr Paula Gonzalez Figueroa, said. For people with allergies, when the immune system overreacts to allergens - like pollen, dust or peanut butter - it produces antibodies called Immunoglobulin E, (IgE). Allergies happen when the body produces excessive IgE in response to otherwise harmless substances, leading to the release of histamine that causes allergic reactions. "We have discovered neuritin prevents excessive formation of IgE that is typically associated with some common forms of allergy and food intolerances," Professor Vinuesa said. Many autoimmune diseases are caused or exacerbated by antibodies that go on to destroy our own tissues and cause autoimmune diseases like lupus and rheumatoid arthritis. "There are over 80 autoimmune diseases, in many of them we find antibodies that bind to our own tissues and attack us instead of targeting pathogens - viruses and bacteria," Dr Paula Gonzalez-Figueroa said. "We found neuritin suppresses formation of rogue plasma cells which are the cells that produce harmful antibodies." The researchers hope the discovery will now form the basis of new treatments. "This could be more than a new drug - it could be a completely new approach to treat allergies and autoimmune diseases," Professor Vinuesa said. "If this approach was successful, we would not need to deplete important immune cells nor dampen the entire immune system; instead, we would only need to use the proteins our own body uses to ensure immune tolerance. "Allergies and autoimmune diseases are both on the rise and we hope this will give us a new way to tackle them."

Scientists discover natural protein that stops allergies and autoimmune conditions

Britain's medicine regulator said anyone with a history of anaphylaxis to a medicine or food should not get the Pfizer-BioNTech COVID-19 vaccine, giving fuller guidance on an earlier allergy warning about the shot.

UK issues anaphylaxis warning on Pfizer vaccine after adverse reactions

Nine out of 10 people in dozens of poor nations could miss out on getting vaccinated against COVID-19 next year because rich countries have hoarded far more doses than they need, campaigners said on Wednesday.

Poor countries seen missing out as rich nations hoard COVID-19 vaccines

American television personality Bethenny Frankel has revealed that she is facing a bit of trouble with her memory and vision due to an allergic reaction after eating fish.

'The Real Housewives of New York City' star sought advice from her fans on her Twitter handle.

"Well tweeps, you're usually smarter than anyone and I keep researching and cannot find out. Can anaphylactic shock affect memory or vision afterwards? I had 20/20 (vision) and it does not appear to be the case now," the 48-year-old star wrote.

"I am getting it all checked out this week but you have all the answers," she added.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet" data-lang="en">
Well tweeps, you’re usually smarter than anyone &amp; I keep researching &amp; cannot find out. Can anaphylactic shock affect memory or vision afterwards? I had 20 20 &amp; it does not appear to be the case now. I am getting it all checked out this week but you have all the answers.
— Bethenny Frankel (@Bethenny) <a href="https://twitter.com/Bethenny/status/1083199264422006785?ref_src=twsrc%5Etfw">January 10, 2019</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

Further, consoling the star and giving her piece of advice, fans wrote, "Pls do speak to your doc/allergist! There are some cases of cognitive issues and eye problems after anaphylaxis. Studies relate this to loss of oxygen to the brain during the reaction," a Twitter user wrote.

"Lack of blood flow from shock can affect vision so sorry," another Twitter user advised.

The star has a rare fish allergy and has been experiencing a traumatic reaction since mid-December. She feels unconscious for 15 minutes after eating a bowl of soup.

"I couldn`t talk, see, thought I had a stroke and dying and told if 5 mins later I'd be dead, 911 and (EpiPen) saved me," she further added.

It's not the first time when the 'Shark Tank' star is experiencing allergic reactions, she had a similar experience when she was traveling in a plane where fish was served.

"Called airline to say I have a fish allergy. Got on and they're serving bass," she tweeted.

"They couldn't serve it they said. Then they were turning around which I protested it would delay people. Cabin asked to not serve it and pilot made an announcement to plane. That was fun. #epilife" she acknowledged.

Moreover, on New Year's Day, the star also re-tweeted a story of an 11-year-old boy who possibly died of an allergic reaction from the smell of cooking fish.

American television personality Bethenny Frankel has revealed that she is facing a bit of trouble with her memory and vision due to an allergic reaction after eating fish.

American television personality Bethenny Frankel has revealed that she is facing a bit of trouble with her memory and vision due to an allergic reaction after eating fish. 'The Real Housewives of New York City' star sought advice from her fans on her Twitter handle. "Well tweeps, you're usually smarter than anyone and I keep researching and cannot find out. Can anaphylactic shock affect memory or vision afterwards? I had 20/20 (vision) and it does not appear to be the case now," the 48-year-old star wrote. "I am getting it all checked out this week but you have all the answers," she added. Well tweeps, you’re usually smarter than anyone & I keep researching & cannot find out. Can anaphylactic shock affect memory or vision afterwards? I had 20 20 & it does not appear to be the case now. I am getting it all checked out this week but you have all the answers. — Bethenny Frankel (@Bethenny) January 10, 2019 × Further, consoling the star and giving her piece of advice, fans wrote, "Pls do speak to your doc/allergist! There are some cases of cognitive issues and eye problems after anaphylaxis. Studies relate this to loss of oxygen to the brain during the reaction," a Twitter user wrote. "Lack of blood flow from shock can affect vision so sorry," another Twitter user advised. The star has a rare fish allergy and has been experiencing a traumatic reaction since mid-December. She feels unconscious for 15 minutes after eating a bowl of soup. "I couldn`t talk, see, thought I had a stroke and dying and told if 5 mins later I'd be dead, 911 and (EpiPen) saved me," she further added. It's not the first time when the 'Shark Tank' star is experiencing allergic reactions, she had a similar experience when she was traveling in a plane where fish was served. "Called airline to say I have a fish allergy. Got on and they're serving bass," she tweeted. "They couldn't serve it they said. Then they were turning around which I protested it would delay people. Cabin asked to not serve it and pilot made an announcement to plane. That was fun. #epilife" she acknowledged. Moreover, on New Year's Day, the star also re-tweeted a story of an 11-year-old boy who possibly died of an allergic reaction from the smell of cooking fish.

Bethenny Frankel experiences allergic reactions, seeks advice from fans

Nestle, the world&#39;s biggest food company, is stepping up its push into medicine with a global deal worth up to 100 million euros ($111 million) to develop and market an experimental milk allergy test for infants.

The Swiss group will pay DBV Technologies 10 million euros upfront for rights to its skin patch test for cow&rsquo;s milk protein allergy (CMPA), with the balance depending on successful development, the two companies said on Tuesday.

Shares in the French biotech company rose 5 percent on the news.

The deal underscores Nestle&#39;s ambitions for its&nbsp;Health&nbsp;Science division, which it believes could eventually generate more than 10 billion Swiss francs ($10 billion) in annual sales.

It also complements the company&#39;s market-leading infant formula business and could help lift sales of products designed for babies with food intolerance.

Nestle has signed a series of similar deals with other small companies in its bid to create a new kind business that is midway between food and pharmaceuticals. The goal is to find new ways to treat, diagnose and prevent a range of diseases, from gastrointestinal problems to Alzheimer&#39;s.

CMPA affects up to 2 or 3 percent of infants and toddlers, according to the companies. Many others, however, have symptoms suggestive of the condition, creating a need for a simple diagnostic test.

Under the terms of the agreement, DBV will be eligible to receive up to 90 million euros in development, regulatory and commercial milestones - on top of the upfront payment - and will also collect royalties on eventual product sales.

&ldquo;This innovation can become the breakthrough diagnostic for CMPA,&quot; said Greg Behar, chief executive of Nestl?&nbsp;Health&nbsp;Science.

The new test will need to go through extensive clinical trials before it is cleared for sale and DBV expects it to be submitted for approval to regulators worldwide by 2021.

Behar&#39;s division, which employs around 3,000 people, is an expanding part of Nestle&#39;s operations.

Given ageing populations around the world and spiralling cases of lifestyle diseases, the Swiss group sees big opportunities in&nbsp;health&nbsp;- but the initiative also poses new challenges by taking it into the highly regulated medical field.

Strategically the shift towards&nbsp;health&nbsp;offers Nestle a hedge against slowing growth in packaged foods and may also offset crackdowns on unhealthy foods blamed for obesity and other lifestyle problems.

The milk allergy test dovetails with Nestle&#39;s presence in infant formula, where it had 22 percent of the market in 2015, according Euromonitor International. It already has a range of products called Althera, Alfare and Alfamino that are designed for infants allergic to cow&rsquo;s milk.

For DBV, the deal is a vindication of its Viaskin patch technology. The company also has a patch to treat peanut allergy in clinical trials, as well as an earlier-stage programme for egg allergy.

Nestle, the world's biggest food company, is stepping up its push into medicine with a global deal worth up to 100 million euros ($111 million) to develop and market an experimental milk allergy test for infants

Nestle, the world's biggest food company, is stepping up its push into medicine with a global deal worth up to 100 million euros ($111 million) to develop and market an experimental milk allergy test for infants. The Swiss group will pay DBV Technologies 10 million euros upfront for rights to its skin patch test for cow’s milk protein allergy (CMPA), with the balance depending on successful development, the two companies said on Tuesday. Shares in the French biotech company rose 5 percent on the news. The deal underscores Nestle's ambitions for its Health Science division, which it believes could eventually generate more than 10 billion Swiss francs ($10 billion) in annual sales. It also complements the company's market-leading infant formula business and could help lift sales of products designed for babies with food intolerance. Nestle has signed a series of similar deals with other small companies in its bid to create a new kind business that is midway between food and pharmaceuticals. The goal is to find new ways to treat, diagnose and prevent a range of diseases, from gastrointestinal problems to Alzheimer's. CMPA affects up to 2 or 3 percent of infants and toddlers, according to the companies. Many others, however, have symptoms suggestive of the condition, creating a need for a simple diagnostic test. Under the terms of the agreement, DBV will be eligible to receive up to 90 million euros in development, regulatory and commercial milestones - on top of the upfront payment - and will also collect royalties on eventual product sales. “This innovation can become the breakthrough diagnostic for CMPA," said Greg Behar, chief executive of Nestl? Health Science. The new test will need to go through extensive clinical trials before it is cleared for sale and DBV expects it to be submitted for approval to regulators worldwide by 2021. Behar's division, which employs around 3,000 people, is an expanding part of Nestle's operations. Given ageing populations around the world and spiralling cases of lifestyle diseases, the Swiss group sees big opportunities in health - but the initiative also poses new challenges by taking it into the highly regulated medical field. Strategically the shift towards health offers Nestle a hedge against slowing growth in packaged foods and may also offset crackdowns on unhealthy foods blamed for obesity and other lifestyle problems. The milk allergy test dovetails with Nestle's presence in infant formula, where it had 22 percent of the market in 2015, according Euromonitor International. It already has a range of products called Althera, Alfare and Alfamino that are designed for infants allergic to cow’s milk. For DBV, the deal is a vindication of its Viaskin patch technology. The company also has a patch to treat peanut allergy in clinical trials, as well as an earlier-stage programme for egg allergy.

Nestle, on health kick, moves into milk allergy testing

allergy

Allergy, News on Allergy, stories on Allergy, articles on Allergy, Allergy stories at Wion, Allergy news, Allergy latest news